NCT07504965 Dementia-friendly Apothecaries as a Resource for Mental Heath in the Elderly
| NCT ID | NCT07504965 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ludwig-Maximilians - University of Munich |
| Condition | Mild Cognitive Impairment |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,020 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,020 participants in total. It began in 2025-07-01 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The DARE study (Dementia-Friendly Apothecaries as a Resource for Mental Health in the Elderly) is a multicenter, prospective cohort study aiming to identify individuals with cognitive impairments early in pharmacies and enhance their access to support services. Partner pharmacies are equipped with memory test stations, and pharmaceutical staff are trained to guide participants. The digital memory test evaluates cognitive, psychosocial, and health factors, displaying results in a traffic light graphic. Participants with concerning results are referred to specialists or support services. The study's primary goals are to establish pharmacies as dementia screening hubs, improve care for affected individuals, promote interdisciplinary collaboration, and lay the groundwork for legal and billing frameworks. An optional subproject validates the screening through neurological evaluations.
Eligibility Criteria
Inclusion Criteria 1. Age: Participants must be 60 years or older at the time of consent. 2. Language Proficiency: Sufficient knowledge of the German language to understand instructions and participate in the study. 3. Cognitive Status: Presence of self-reported, relative-reported, or pharmacist-identified cognitive impairments (e.g., memory problems or mild cognitive changes). 4. Consent: Ability to provide informed consent voluntarily. Exclusion Criteria 1. Severe Sensory Impairments: Participants unable to see or hear well enough to complete the digital assessments or questionnaires. 2. Previous Dementia Diagnosis: Individuals with a prior formal diagnosis of dementia, whether with or without underlying pathology. 3. Severe Cognitive or Physical Impairments: Any condition that would prevent meaningful participation in the digital tests or structured screening process. These criteria aim to ensure that the study includes participants at risk of early cognitive decline while excluding those for whom the interventions or assessments would not be feasible or relevant.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07504965 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 90 Years, studying Mild Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07504965 currently recruiting?
Yes, NCT07504965 is actively recruiting participants. Contact the research team at psy.alzheimerzentrum@med.uni-muenchen.de for enrollment information.
Where is the NCT07504965 trial being conducted?
This trial is being conducted at Munich, Germany.
Who is sponsoring the NCT07504965 clinical trial?
NCT07504965 is sponsored by Ludwig-Maximilians - University of Munich. The trial plans to enroll 1,020 participants.